How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

690 results for

Dysuria in Children

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Neutropenic sepsis: How should I assess a person with suspected neutropenic sepsis?

/carers about: Any known . Any recent fever or rigors. Be aware that people with neutropenic sepsis may not present with fever, and may present with hypothermia. Any symptoms suggesting a focus of infection, such as dysuria, diarrhoea, or productive cough. Clinical features suggesting dehydration, such as reduced urine output in the past 18 hours. Any altered behaviour, mental state, or cognition. See the CKS topic on for more information. If the person is known to have cancer, the type of cancer (...) exanthems in people who are immunosuppressed may present atypically. Weak high-pitched or continuous cry (in children under 5 years of age). Any breach of skin integrity (for example cuts, burns, or skin infections) or other skin signs suggesting infection or mucositis. See the CKS topics on and for more information. Dry mucous membranes or other signs of dehydration. See the CKS topic on for more information on assessment. The possible underlying source of infection. Be aware that people who

2017 NICE Clinical Knowledge Summaries

142. Chilblains: Nifedipine

dihydropyridines (theoretical risk of cross-reactivity) or any of the excipients. To people with unstable angina, cardiogenic shock, significant aortic stenosis, unstable angina, or within 1 month of myocardial infarction. To women who are pregnant or breastfeeding — seek specialist advice if these women require treatment. To children under the age of 18 years — safety in children has not been established. To people taking rifampicin. Rifampicin induces the cytochrome P450 system —bioavailability of nifedipine (...) formulations may be associated with large variations in blood pressure and reflex tachycardia. Uncommon — angioedema; anxiety; chills; dyspnoea; dysuria; epistaxis; erectile dysfunction; hypersensitivity reactions; jaundice; joint swelling; migraine; myalgia; nasal congestion; nocturia; paraesthesia; polyuria; pruritus; rash; sleep disturbance; sweating; syncope; tachycardia; tremor; urticaria; vertigo; visual disturbance. Cardiac ischaemic pain has been reported, in a small proportion of people, after

2017 NICE Clinical Knowledge Summaries

143. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

is relatively straightforward when symptoms are clearly present and the diagnosis was previously made in childhood. However, if not established during childhood, the diagnosis of ADHD in adults can be difficult. Particularly important is to interview at least one adult informant (such as a parent or a close relative), who can give information about the behaviour of the patient as a child. As most adults have a recall bias, it is difficult for them to recall the onset, severity and persistence of ADHD (...) Crescenzo , Samuele Cortese , , Nicoletta Adamo , Luigi Janiri Statistics from Altmetric.com Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric conditions, with a pooled worldwide prevalence estimated at about 5% in school-aged children and persistence of impairing symptoms in adulthood in up to 65% of cases. The pooled estimated prevalence of ADHD (as categorical diagnosis) in adults is around 2.5%. ADHD is characterised by a persistent and impairing

2017 Evidence-Based Mental Health

144. Fever in under 5s: assessment and initial management

Contents Overview 5 Who is it for? 5 Introduction 6 Patient-centred care 8 Key priorities for implementation 9 Thermometers and the detection of fever 9 Clinical assessment of the child with fever 9 Management by remote assessment 9 Management by the non-paediatric practitioner 10 Management by the paediatric specialist 10 Antipyretic interventions 10 1 Recommendations 12 1.1 Thermometers and the detection of fever 12 1.2 Clinical assessment of children with fever 13 1.3 Management by remote assessment (...) : providing the parent or carer with verbal and/or written information on warning symptoms and how further healthcare can be accessed (see section 1.7.2) arranging further follow-up at a specified time and place liaising with other healthcare professionals, including out-of-hours providers, to ensure direct access for the child if further assessment is required. [2007] [2007] Management by the paediatric specialist Perform the following investigations in infants younger than 3 months with fever: full

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

145. Zavicefta (ceftazidime / avibactam) - infections

literature substituting/supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0052/2015 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0052/2015 was not yet completed as some measures were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 (...) be administered after haemodialysis on haemodialysis days (see Table 2). Haemofiltration There is insufficient data to make specific dosage adjustment recommendations for patients undergoing continuous veno-venous haemofiltration. Peritoneal dialysis There is insufficient data to make specific dosage adjustment recommendations for patients undergoing peritoneal dialysis. Hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment (see section 5.2). Paediatric population Safety

2016 European Medicines Agency - EPARs

146. Point-of-care testing for urinary tract infections

by Anacleto et al., 26 the authors compared the accuracy of the Uricult Trio device against conventional urine microscopy and culture. They tested 198 mid-stream clean-catch, randomly voided (i.e. urine collected at any point in the stream) or catheterized urine samples from children aged 0-7 if the sample had been screened positive for nitrites or leukocyte esterase with a urine dipstick test. A urine sample was obtained from children 2 years of age if they presented with dysuria, urgency, flank pain (...) when using the cut-off value of >5×10 4 CFU/ml. The lower accuracy of the study can be explained to a degree by the higher cut-off value for significant bacteriuria. Paediatric patients 6. Waisman et al. 35 tested the diagnostic accuracy of Uriscreen® compared to urine culture in early detection of UTIs in urine specimens obtained through midstream void technique, bladder catheterization, or suprapubic aspiration from children aged 1 month to 17 years of age. The study was conducted over a period

2016 Publication 4878904

147. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals ? protocol version 5.3

-producing C. difficile organisms in stool. ? SYS-CSEP: no change in the definition, but change of the name from ‘clinical sepsis’ to ‘treated unidentified severe infection’ in adults and children, to differentiate this last-resort HAI case definition from the modern concept of sepsis based on organ dysfunction. TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 3 Objectives The objectives of the ECDC point prevalence survey of healthcare (...) on maternity and paediatric wards if born before/at 8 a.m. (see also under neonates). Exclude day cases: ? patients undergoing same day treatment or surgery; ? patients seen at outpatient department; ? patients in the emergency room; ? dialysis patients (outpatients). Note: Decision to include/exclude patients is based on information available at 8 a.m. on the day of the survey. Figure 1. Examples of included and excluded patients in the point prevalence survey Legend. W1: ward 1, W2: ward 2 Note: Include

2016 European Centre for Disease Prevention and Control - Technical Guidance

148. Edistride - dapagliflozin

this medicine. Pediatric population Product labeling: Posology and method of administration: Paediatric population The safety and efficacy of dapagliflozin in children aged 0 to < 18 years have not yet been established. No data are available. Patient information Children and adolescents Forxiga is not recommended for children and adolescents under 18 years of age, because it has not been studied in these patients. Not applicable Pregnancy / Nursing mothers Product labeling: Fertility, pregnancy (...) 82.1 of Regulation (EC) No 726/2004. Information on Paediatric requirements Not applicable Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. Licensing status The cross-referred product Forxiga

2015 European Medicines Agency - EPARs

149. Ebymect - dapagliflozin / metformin

: Warnings and precautions If you are 75 years old or older, you should not start taking this medicine. This is because you may be more prone to some side effects. If you are taking another medicine for diabetes that contains “pioglitazone”, you should not start taking this medicine. Not applicable Pediatric population Product labeling: Posology and method of administration: Paediatric population The safety and efficacy of Xigduo in children aged 0 to < 18 years have not yet been established. No data (...) of dapagliflozin and metformin as separate tablets. The legal basis for this application refers to: Article 10(c) of Directive 2001/83/EC – relating to informed consent from a marketing authorisation holder for an authorised medicinal product. The application submitted is composed of administrative information, quality, non-clinical and clinical data with a letter from AstraZeneca AB allowing the cross reference to relevant quality, non-clinical and/or clinical data. Information on Paediatric requirements

2015 European Medicines Agency - EPARs

150. Zerbaxa - ceftolozane / tazobactam

of administrative information, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0126/2014 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0126/2014 was not yet completed as some (...) should be administered at the earliest possible time following completion of haemodialysis) *CrCL estimated using Cockcroft-Gault formula **All doses of Zerbaxa are administered intravenously over 1 hour and are recommended for all indications. The duration of treatment should follow the recommendations in Table 1. Hepatic impairment No dose adjustment is necessary in patients with hepatic impairment (see section 5.2). Paediatric population The safety and efficacy of ceftolozane/tazobactam

2015 European Medicines Agency - EPARs

151. Xydalba - dalbavancin

that Dalbavancin was considered to be a new active substance. The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0245/2013 on the agreement of a paediatric investigation

2015 European Medicines Agency - EPARs

152. Senshio - ospemifene

. The applicant indicated that ospemifene was considered to be a new active substance (refer to sections on New active Substance status for further information). The application submitted is composed of administrative information, complete quality data, non- clinical and clinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies. Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006 (...) , a feeling of pressure and bleeding (particularly associated with sexual activity). VVA is also associated with urinary symptoms including urethral discomfort, frequency, hematuria, urinary tract infection, dysuria, and stress incontinence (MacBride et. al., 2010). Over time these symptoms, especially dyspareunia, can lead to female sexual dysfunction and subsequent emotional distress. Despite the impact of VVA on women’s health, this condition is underdiagnosed and undertreated, with only an estimated

2015 European Medicines Agency - EPARs

153. Avibactam sodium / ceftazidime (Avycaz)

-Disease Interactions 145 7.5.5 Drug-Drug Interactions 145 7.6 Additional Safety Evaluations 145 7.6.1 Human Carcinogenicity 145 7.6.2 Human Reproduction and Pregnancy Data 146 7.6.3 Pediatrics and Assessment of Effects on Growth 146 7.6.4 Overdose, Drug Abuse Potential, Withdrawal and Rebound 147 7.7 Additional Submissions / Safety Issues 147 8 POSTMARKET EXPERIENCE 149 9 APPENDICES 151 9.1 Literature Review/References 151 9.2 Labeling Recommendations 151 9.3 Advisory Committee Meeting 153 REFERENCES (...) to recommend routine pharmacovigilance as a sufficient strategy for postmarket risk evaluation. 1.4 Recommendations for Postmarket Requirements and Commitments The Applicant submitted a deferral request with their initial pediatric study plan, which assumes that efficacy can be extrapolated from adult data for cIAI and cUTI in pediatric patients as young as 3 months of age. Pursuant to PREA requirements, an open-label single-dose trial to evaluate the pharmacokinetic, safety and tolerability of CAZ-AVI

2015 FDA - Drug Approval Package

154. The Role of Early Goal-Directed Therapy in Severe Sepsis and Septic Shock

The Role of Early Goal-Directed Therapy in Severe Sepsis and Septic Shock Emergency Medicine > Journal Club > Archive > July 2015 Toggle navigation July 2015 The Role of Early Goal-Directed Therapy in Severe Sepsis and Septic Shock Vignette You are working a shift in TCC one busy afternoon when a patient is brought in by EMS for flank pain and a fever. You enter the room the find a 60­‐year female with a history of hypertension who is in no distress. She complains of dysuria, right flank pain (...) recognition and management were vital, and it was likely this increased awareness that has resulted in the drastic reduction in mortality observed. Intranet Locations Contact Us Follow Us: F: (314) 362-0478 EM Statistics Adult ED Visits: 95,600 Pediatric ED Visits: 55,000 Trauma Center: Level 1 Residency Type: 1-4 Fellowship Programs: 5 FT Faculty: 46 Residents: 53 | | | | © 2019 by Washington University in St. Louis One Brookings Drive, St. Louis, MO 63130

2015 Washington University Emergency Medicine Journal Club

155. Nonstented Tubularized Incised Plate Distal Hypospadias Repair: A Single Center 5 Years' Experience. (Abstract)

Nonstented Tubularized Incised Plate Distal Hypospadias Repair: A Single Center 5 Years' Experience. To report our immediate and delayed outcomes of nonstented tubularized incised plate (TIP) distal hypospadias repair.We retrospectively reviewed all charts of children who underwent distal hypospadias repair in a single children's hospital from 2013 to 2018. Patients' demographics, hypospadias characteristics, operative technique, and immediate and delayed outcomes were recorded.Of 280 (...) consecutive distal hypospadias repairs that were identified, 74 were excluded due to the use of a repair other than TIP. Eleven stented TIP repairs were excluded as well. Of 195 nonstented repairs, immediate postoperative voiding complications were recorded in 11 (5.6%) and included multiple/split stream in 6 (3%), dysuria and voiding difficulty in 2 (1%), urinary retention in 2 (1%), and gross hematuria that spontaneously resolved in 1 (0.5%). Late follow up was recorded in 142 of 195 (72.8%) repairs

2020 Urology

156. Eosinophilic cystitis and nephrogenic adenoma of the bladder: a rare association of 2 unusual findings in childhood. (Abstract)

Eosinophilic cystitis and nephrogenic adenoma of the bladder: a rare association of 2 unusual findings in childhood. Neither eosinophilic cystitis nor nephrogenic adenoma is often diagnosed in children, with few pediatric cases being reported in the literature. Although these maladies share the same predisposing conditions, namely, chronic irritation or injury to the urothelium and lower urinary tract and symptoms such as dysuria, hematuria, and urinary frequency, their concomitance

2011 Journal of Pediatric Surgery

157. Bladder Cancer Treatment (PDQ®): Health Professional Version

is thought to play a key role in carcinogenesis in these settings. Clinical Features Bladder cancer typically presents with gross or microscopic hematuria. Less commonly, patients may complain of urinary frequency, nocturia, and dysuria, symptoms that are more common in patients with carcinoma in situ . Patients with upper urinary tract urothelial carcinomas may present with pain resulting from obstruction by the tumor. Urothelial carcinomas are often multifocal—the entire urothelium needs

2018 PDQ - NCI's Comprehensive Cancer Database

158. Bladder and Other Urothelial Cancers Screening (PDQ®): Health Professional Version

Central citations Links to PubMed Similar articles in PubMed [PDQ Cancer Information Summari...] Review Bladder Cancer Treatment (PDQ®): Health Professional Version PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries. 2002 [PDQ Cancer Information Summari...] Review Childhood Bladder Cancer Treatment (PDQ®): Health Professional Version PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries. 2002 [PDQ Cancer Information Summari...] Review Neuroblastoma Screening (PDQ (...) range from 13% to 34.5%.[ - ] Other presenting symptoms include dysuria, urinary frequency or urgency, and less commonly, flank pain secondary to obstruction, and pain from pelvic invasion or bone metastases. Diagnosis and staging usually begin with cystoscopy. Full evaluation of the upper and lower urinary tract is required.[ ] Histopathology More than 90% of bladder cancers diagnosed in the United States are pure TCCs or TCCs mixed with other histologies, primarily SCC, adenocarcinoma, or both

2018 PDQ - NCI's Comprehensive Cancer Database

159. Chronic prostatitis and chronic pelvic pain syndrome

, inguinal or rectal regions. 17,22 In addition, they may report dysuria, or pain during or after ejaculation. 17 Findings from a retrospective analysis of clinical records (n=1,563) indicate that the most prevalent localisation for pain is the perineal region (63% of patients), followed by the testicular, pubic and penile areas. 10 Tenderness in the abdominal/pelvic region is also reported by patients with CP/CPPS, with the most common sites including the prostate and pelvic floor muscles. 23,24 (...) symptoms experienced by CBP and CP/CPPS patients. 25-27 Neuropathic pain is also a feature of CP/CPPS and is described in more detail in Box 1. LUTS are also a common clinical presentation, 4,22,28 with cohort studies reporting at least one such symptom in 39– 68% of patients. 4,29 LUTS include voiding symptoms (for example, weak stream, straining and hesitancy) or storage symptoms (for example, urgency with or without urgency incontinence, increased urinary frequency, nocturia and dysuria). 17,30

2015 Prostate Cancer UK

160. Dietary interventions for preventing complications in idiopathic hypercalciuria. (Abstract)

life stages; people with the condition are prone to developing oxalate and calcium phosphate kidney stones. In some cases, crystallised calcium can be deposited in the renal interstitium, causing increased calcium levels in the kidneys. In children, idiopathic hypercalciuria can cause a range of comorbidities including recurrent macroscopic or microscopic haematuria, frequency dysuria syndrome, urinary tract infections and abdominal and lumbar pain. Various dietary interventions have been described (...) that aim to decrease urinary calcium levels or urinary crystallisation.Our objectives were to assess the efficacy, effectiveness and safety of dietary interventions for preventing complications in idiopathic hypercalciuria (urolithiasis and osteopenia) in adults and children, and to assess the benefits of dietary interventions in decreasing urological symptomatology in children with idiopathic hypercalciuria.We searched the Cochrane Renal Group's Specialised Register (23 April 2013) through contact

2014 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>